Abstract: An ex-vivo lung solution for machine perfusion of donor lungs on OCS. The solution may be mixed with whole blood or packed red blood cells to form the OCS lung perfusion solution.
Type:
Grant
Filed:
July 20, 2022
Date of Patent:
January 2, 2024
Assignee:
TRANSMEDICS, INC.
Inventors:
Waleed H. Hassanein, Ihab Abdel Fattah, Paul Lezberg, Tamer I. Khayal, Robert Havener, Anas Abdelazim
Abstract: Phenotypic antimicrobial susceptibility testing (AST), the gold-standard diagnostic that indicates whether an antimicrobial will be clinically effective, often suffer the slowest times-to-result for the most resistant pathogens. Here we introduce novel assays to be performed in parallel with standard AST assays that provide additional resistance information and enable rapid, same-shift reporting of AST results for a plurality of pathogens.
Abstract: Embodiments of the methods and compositions provided herein relate to inducing hair growth in a subject. Some embodiments include screening for agents to modulate hair growth.
Type:
Grant
Filed:
May 22, 2020
Date of Patent:
December 12, 2023
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.
Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
Type:
Grant
Filed:
October 16, 2020
Date of Patent:
December 12, 2023
Assignee:
United Therapeutics Corporation
Inventors:
Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
Type:
Grant
Filed:
September 8, 2021
Date of Patent:
December 12, 2023
Assignee:
United Therapeutics Corporation
Inventors:
Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
Abstract: A composition and methods of using the composition for the control of mollusks are provided, which include an effective amount of one or more isolated Phasmarhabditis nematodes, wherein at least one of the isolated nematodes is P. californica, P. papillosa or P. hermaphrodita, and wherein the P. hermaphrodita does not comprise Moraxella osloensis.
Type:
Grant
Filed:
August 28, 2020
Date of Patent:
November 28, 2023
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Irma Tandingan De Ley, Rory McDonnell, Timothy Paine
Abstract: Provided is a composition for preventing or ameliorating a functional gastrointestinal disorder whose active ingredient is Bifidobacterium breve MCC1274 (FERM BP-11175). A composition for preventing or ameliorating a functional gastrointestinal disorder in the present technology can prevent or improve constipation or frequent bowel movements, regulate the number of bowel movements, improve stool quality, prevent or improve constipation, prevent or ameliorate bloating, or prevent or improve abdominal discomfort. Disclosed is a composition for preventing or ameliorating a functional gastrointestinal disorder accompanied by anxiety disorder. A composition for preventing or ameliorating a functional gastrointestinal disorder in the present technology can be used in a pharmaceutical composition or in a food or beverage composition.
Type:
Grant
Filed:
March 12, 2019
Date of Patent:
November 28, 2023
Assignee:
Morinaga Milk Industry Co., Ltd.
Inventors:
Mai Murata, Junichi Minami, Hazuki Maehata
Abstract: The present invention relates to a method of isolating a mesenchymal stem cell population from the amniotic membrane of the umbilical cord, the method comprising cultivating umbilical cord tissue in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population isolated from the amniotic membrane of the umbilical cord, wherein at least about 90% or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.
Abstract: The invention provides an ex-vivo method, i.e. an in vitro method, for genetically modifying cells of a vascularised tissue, which can be anorgan, during normothermic or subnormothermic perfusion without damaging the tissue or its cells due to oxygen undersupply. The method enables keeping the vascularised tissue at normothermic or subnormothermic conditions over a sufficient period of time to genetically modify the cells e.g. with viral vectors.
Type:
Grant
Filed:
May 23, 2018
Date of Patent:
November 14, 2023
Assignee:
MEDIZINISCHE HOCHSCHULE HANNOVER
Inventors:
Rainer Blasczyk, Constanca Ferreira De Figueiredo
Abstract: Provided herein are non-naturally occurring microbial organisms having a pathway for production of (3R)-hydroxybutyl (3R)-hydroxybutyrate, wherein the organism can further include a (R)-1,3-butanediol pathway, a (3R)-hydroxybutyrate pathway, a (3R)-hydroxybutyryl-CoA pathway, an acetoacetate pathway, an acetoacetyl-CoA pathway, a (3R)-hydroxybutyl-ACP pathway, or an acetoacetyl-ACP pathway. Additionally provided are methods and processes for producing and isolating (3R)-hydroxybutyl (3R)-hydroxybutyrate using the microbial organisms, and various compositions having the (3R)-hydroxybutyl (3R)-hydroxybutyrate. Still further provided are methods of treating or preventing a disease, disorder or condition using the (3R)-hydroxybutyl (3R)-hydroxybutyrate produced by the microbial organisms of the invention.
Type:
Grant
Filed:
May 23, 2014
Date of Patent:
November 14, 2023
Assignee:
Genomatica, Inc.
Inventors:
Benjamin Adelstein, Robin E. Osterhout, Mark J. Burk
Abstract: Disclosed herein is a cell harvesting instrument suitable for concentrating cells from a source suspension of cells and/or washing said cells, the instrument comprising: a housing for accommodating mechanical elements including at least one fluid pump, at least one valve; and a processing kit removably insertable into the housing, said kit including a generally flat frame having or supporting plural sealed fluid paths arranged in a generally flat plane and such that fluids in the paths do not contact said mechanical elements, wherein at least portions of the fluid paths comprise flexible tubes, the outer surfaces of which are manipulatable by the or each fluid pump, to provide fluid flow in one or more of the paths and/or by the or each valve to restrict fluid flow in one or more of the paths. In an embodiment, the kit comprises also a fluid processing reservoir and a filter suitable for separating cells from fluid in said paths.
Type:
Grant
Filed:
December 22, 2016
Date of Patent:
November 7, 2023
Assignee:
GLOBAL LIFE SCIENCES SOLUTIONS USA LLC
Inventors:
Weston Blaine Griffin, Dan Harris, Jim Dowling, Dan O'Sullivan
Abstract: A novel macroscale, contactless, label-free method to print in situ three-dimensional (3D) particle assemblies of different morphologies and sizes is demonstrated using non-adherent (blood) and adherent (MCF-7 and HUVEC) cells. This method of manipulating particles such as cells or biological moleules does not necessarily require the use of nozzles that can contaminate the cell suspension, or to which cells can adhere. Instead, the intrinsic diamagnetic properties of particles such as cells are used to magnetically manipulate them in situ in a nontoxic paramagnetic medium, creating various shapes such as (a) rectangular bar, (b) three-pointed star, and (c) spheroids of varying sizes. A normal distribution of 3D cell structures is produced when formed through magnetic assembly. The use of this method in co-culturing of different cell lines is also demonstrated.
Type:
Grant
Filed:
November 1, 2018
Date of Patent:
October 17, 2023
Assignee:
McMaster University
Inventors:
Abdel Rahman Abdel Fattah, Rakesh Prasad Sahu, Fei Geng, Sarah Mishriki, Elvira Meleca, Ishwar K. Puri, Suvojit Ghosh
Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.
Abstract: A method of preparing and obtaining cell aggregates having increased oxygenation abilities. The method includes the preparation of fluorinated polymeric microparticles. Once the fluorinated polymeric microparticles are prepared, they are combined with mammalian cells to create the cell aggregates having increased oxygenation.
Abstract: The present invention provides a novel oocyte maturation medium or/and embryo culture medium with a chemically defined supplement to produce matured oocytes at high efficiency. The inventive medium or supplement comprises three growth factors, namely, fibroblast growth factor 2 (FGF2), leukemia inhibitory factor (LIF), and insulin-like growth factor 1 (IGF-1) in a synergistic combination. Methods for oocyte and embryo culture are also provided.
Type:
Grant
Filed:
June 3, 2020
Date of Patent:
September 12, 2023
Assignee:
The Curators of the University of Missouri
Inventors:
Ye Yuan, Lee D. Spate, Randall S. Prather, R. Michael Roberts
Abstract: The present invention provides a sufficiently effective medicine for treatment and/or prevention of ischemic diseases, without performing isolation of therapeutic cells or removal of deleterious cells from blood cells/hemocytes. The blood cells and/or the hemocytes are subjected to the action of a saccharide. The saccharide is a monosaccharide, a disaccharide, a trisaccharide, a polysaccharides, or a copolymer containing a monosaccharide, a disaccharide, or a trisaccharide as a component. The saccharide is a copolymer of sucrose and epichlorohydrin.
Type:
Grant
Filed:
March 18, 2016
Date of Patent:
September 5, 2023
Assignee:
Foundation for Biomedical Research and Innovation at Kobe
Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.
Type:
Grant
Filed:
July 30, 2013
Date of Patent:
August 22, 2023
Assignees:
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.
Abstract: Multi-use biosensors are disclosed that include enzymes that have been modified to reduce the solubility thereof; the multi-use biosensors are used to detect analytes in fluidic biological samples, and the biosensors also maintain their enzyme activity after many uses. Multi-sensor arrays are disclosed that include multiple biosensors. Also disclosed are methods of producing and using these devices.
Abstract: The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids.
Type:
Grant
Filed:
January 15, 2020
Date of Patent:
August 15, 2023
Assignee:
Koninklijke Nederlandse Akademie Van Wetenschappen
Inventors:
Meritxell Huch Ortega, Johannes Carolus Clevers, Sylvia Fernandez Boj